Archive

Posts tagged under: real-world evidence

Join MDCPartners at Clinical Trial Innovation Summit 2017

CHI’s 6th Annual Clinical Trial Innovation Summit brings together more than 250 leaders from across pharma, biotech and academia to share case studies and best practices on effective clinical trial management and vendor oversight. Of course MDCPartners’ ta-Scan team will be there too. The summit features 6 co-located conferences and 3 dinner short courses. Multiple registration options are available. Download the digital brochure for all details.

2017 Program Highlights

The 2017 Clinical Trial Innovation Summit program focuses on key issues and opportunities in the clinical trial industry, including patient recruitment, site selection, data integration, existing data sources, mobile tech, project management, outsourcing, vendor management, budgeting and contracting, quality (QbD) in trial conduct, risk-based monitoring and clinical auditing.

  • ICH E6 guidance, including gap analysis, action plans, and project plans from clinical trial quality and risk management expert Andy Lawton
  • An assessment of current and future trial technologies: social media, search engine optimization, targeted digital advertising, artificial intelligence and virtual reality
  • Real examples of big data analytics in clinical trials from Takeda, Bayer, Janssen, and BMS
  • Proven strategies for determining timelines, key activity needs, and effective communication for clinical trial outsourcing
  • Case studies from AbbVie, Merck, and Samumed on new methods of risk mitigation, issue management, and oversight plans to ensure quality clinical trials
  • How to navigate regulation and data quality and quantity challenges of wearables, sensors and mHealth from pharma teams in the trenches
  • Lessons learned from AstraZeneca, BMS, Gilead, and several others at the frontline of RBM roll-out

Join us in Boston

Would you like to know how we can help with your company’s data challenges, using our clinical business intelligence software ta-Scan and our other data solutions? Then feel free to pop by at Booth #3 in the exhibition hall (Essex North / Center Ballroom) or make an appointment with MDCPartners Chief Scientific Officer David Cocker or Director of Business Development, North America Matt Tumasz. They will gladly show you our state of the art software tools.

Register Today

Use our discount code MDPCTL for $200 off your registration cost.*

How to Register:
Online: https://chidb.com/reg/ctl/reg.asp
By telephone: +1 781-972-5400

We hope to see you in Boston!

* Our clients and colleagues will receive $200 off for commercial attendees or $100 off for academic, government and hospital-affiliated attendees. You must mention priority keycode MDPCTL to receive the registration discount. Alumni, Twitter, LinkedIn, Facebook or any other promotional discounts cannot be combined. Discounts not applicable on event short courses. This discount does not apply to previously registered attendees.

NEWS RELEASE: MDCPartners launches new ta-Scan software that ‘will revolutionize’ the way pharmaceutical companies plan for the future

Antwerp, Belgium | 24 January 2017 – MDCPartners today launches ta-Scan 5, an update of its global web-based platform that analyses clinical trial data. The new platform is set to revolutionize the way pharmaceutical researchers plan for the future, by providing unrivaled insights that will help inform future business decisions.

The new ta-Scan 5 is the first software of its kind to use exceptionally powerful algorithms to analyse clinical data from multiple global public sources in its patented Trial Cloud®. The new version 5 will mean that pharmaceutical companies are able to obtain more valuable insights on clinical research than ever before, via a more streamlined process.

The software will allow companies to go into more detail on clinical trial research than ever before, with access to over 250,000 clinical trials and 7 million scientific and clinical experts. This will provide unique insights on specific compounds, research institutes, clinical centers, patient populations, key investigators and competitor analysis to help strategic decision making.

“We believe the opportunity in clinical business intelligence is the freedom to look at data from multiple sources, from any region, combined into one system that’s easy to use. The new ta-Scan 5 does just that – it taps into vast amounts of information and provides comprehensive analysis that can be broken down easily. Pharmaceutical companies are now starting to realize their opportunities in gathering the most valuable business intelligence, and I believe the ability of this software will fundamentally change the way clinical research is planned and executed across the industry,” comments David Cocker, CSO for MDCPartners, who is presenting this week at the SCOPE Summit in Miami, Florida.

“For the first time ever, MDCPartners has been able to simplify complex trial-related queries and perform deep analysis using the most powerful algorithms yet. Using Real World Solutions, we can link internal and external information together through a portal, to generate a comprehensive landscape and get a full view of where the competing trials are conducted, and where the patient populations are. Before, we couldn’t link this information, now it is at our fingertips,” comments Dr Bart Naudts, Lead Data Architect at MDCPartners.

The ta-Scan web platform has been used by pharmaceutical and biotech researchers for the last decade. It has transformed and advanced the process of intelligence gathering and analyzes across the industry.

Media Enquiries

MDCPartners
Mireille De Cré
mireille.decre@mdcpartners.be
+32 (0) 3 870 97 50

Tonic Life Communications
Stan Jackson / Chrissie Hannah
stan.jackson@toniclc.com / chrissie.hannah@toniclc.com
+44 (0) 774 771 8279 / +44 (0)777 253 4646

***ENDS***

Notes to Editors

About ta-Scan

ta-Scan is an intelligence web platform for clinical development, which analyses data for trial planning, expert profiling, disease landscape and competitive intelligence, for researchers in the pharmaceutical and biotech industry. It was launched nearly a decade ago to transform and advance the intelligence gathering and analyses that enable clinical development.

Powerful algorithms enable researchers to bypass print publications, restrictive registries and dense databases for the insights they need to make evidence-based decisions. With ta-Scan, users can locate key opinion leader (KOL) associations, investigators with specific therapeutic experience, or institutes with the capacity to conduct complex protocols.

To find out more about ta-Scan, please visit: www.ta-scan.com/product

About ta-Scan 5

ta-Scan 5 is the updated model of ta-Scan, which was recently launched by MDCPartners at the SCOPE Summit in Miami, Florida, in January 2017. It offers a uniquely streamlined and simplified intelligence gathering process and improves data access and value, allowing for a more intuitive, business-oriented workflow.

ta-Scan 5 features a refined and robust search engine tool which activates alternative information pathways with the flexibility to adjust query filters with ease. The number and potential combination of trial-related queries is unrestricted, meaning that hundreds of data classes are semantically connected that can be accessed by one query.

To find out  more about ta-Scan 5, please visit: https://vimeo.com/mdcp/ta-scan5

About MDCPartners

Founded in 1999, MDCPartners specialises in business intelligence and strategic consultancy for the pharmaceutical and biotech industry. They combine drug development expertise with the latest data sciences to provide clinical trial optimisation, medical expert identification and competitive intelligence.

MDCPartners is a leader in the field of data mining and semantic processing. With their patented data solutions, their clients transform millions of dispersed data points into meaningful intelligences.

MDCPartners is headquartered in Antwerp, Belgium, with sales offices in the USA and Japan. It has three flagship products for global pharmaceutical data solutions, including:

  • ta-Scan: the flagship product ta-Scan is a web business intelligence platform that analyses clinical development programmes, trial and site data, and involvement of medical experts
  • normScan: the medical device standards monitoring tool, normScan, is tailored to the client’s medical device portfolio. normScan tracks all relevant device standards and regulatory documents that have been published or are in development
  • Real World Solutions: an evolving area of business for MDCPartners are the customised data solutions, which tap into a robust inventory of algorithms and unique visualisation tools. Users can gain optimal insights from data either as stand-alone or combined with public data

To find out more about MDCPartners, please visit: www.mdcpartners.be

Categories

 

Tags

 

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page